{
    "comments": "Danuglipron (PF-06882961) is a small molecule, non-peptide, orally active agonist of the human (and monkey) glucagon-like peptide-1 receptor (GLP-1R) <Reference id=41855/><Reference id=43828/>. It was developed as a once-daily pill alternative to established peptide GLP-1R agonists that are used to treat diabetes, and in some instances, obesity (<i>e.g. </i><Ligand id=1133/> and <Ligand id=9724/>).",
    "bioactivityComments": "Danuglipron appears to be a partial agonist in recruiting &beta;-arrestin-2 to GLP-1R (EC<sub>50</sub> 490 nM) <Reference id=43828/>. It exhibits moderate hERG inhibitory activity (IC<sub>50</sub> 4.3 &mu;M) <Reference id=48981/> which suggests the risk of cardiac toxicity.",
    "clinicalUse": "Results from phase 1 studies of danuglipron (PF-06882961) have been published <Reference id=43895/><Reference id=46127/>. In spring 2025 Pfizer discontinued development of danuglipron following signs of possible drug-induced liver injury in a trial participant <Reference id=49054/>.",
    "mechanismOfAction": "",
    "absorptionAndDistribution": "",
    "metabolism": "",
    "elimination": "",
    "populationPharmacokinetics": "",
    "organFunctionImpairment": "",
    "immuno": "",
    "gtmp": ""
}